Background
==========

*H19* is a paternally imprinted gene located at 11p15.5, which encodes a non-coding transcript. Although the role of genomic imprinting in bladder cancer is not well understood, previous studies have described *H19* over-expression in these tumors. It is well established that a Differentially Methylated Region (DMR) regulates its maternal monoallelic expression by acting as an insulator that precludes the binding of the transcriptional factor CTCF in the paternal allele.

Materials and methods
=====================

DNA methylation *status* of two distinct regions of the *H19* gene was evaluated: the sixth CTCF-binding site located in the DMR (qMSP, Quantitative Real Time Methylation Specific Polymerase Chain Reaction) and the promoter-associated CpG island (MS-HRM, Methylation-Sensitive High Resolution Melting analysis) in a total of 48 tumoral samples (37 of them matched with normal adjacent tissue).

Results
=======

Using a pool of blood samples obtained from healthy young adults as reference to the normal imprinting, higher methylation levels of the CTCF-binding site was detected in bladder tumors compared to the normal adjacent tissue (*p*=*0.0031*). Gains of methylation were more frequently detected in non-invasive (*p*=*0.0425*) and non-recurrent (*p*=*0.0399*) papillary bladder tumors. While DNA methylation levels of *H19* promoter region varied from 10 to 50% in normal adjacent bladder tissues, tumoral samples showed greater variation (10 to 100% of methylation). Heterogeneous patterns of CpG methylation were also detected in nine tumoral samples.

Conclusion(s)
=============

Our data suggest that aberrant DNA methylation is an epigenetic change potentially associated with loss of imprinting of the *H19* gene in bladder cancer.
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